This was the stock's third consecutive day of losses.

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 2.35% to $6.10 Tuesday, on what proved to be an all-around positive ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $7.87, with InvestingPro data showing the stock is currently trading below its Fair... In a recent ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

**NM signifies a non meaningful value. A dash signifies the data is not available.

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter in the prior year, the firm earned $0.14 EPS.